Log In
Print
BCIQ
Print
Print this Print this
 

CB 2679d, FIX-NG

  Manage Alerts
Collapse Summary General Information
Company Catalyst Biosciences Inc.
DescriptionRecombinant Factor IX
Molecular Target Factor IX
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPreclinical
Standard IndicationBleeding
Indication DetailsTreat and prevent bleeding in hemophilia B
Regulatory Designation

Partner

Isu Abxis Co. Ltd.


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$40.0M

$40.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today